Novo Nordisk A/S (LON:0QIU)

Market Cap	245.80B
Revenue (ttm)	34.00B
Net Income (ttm)	11.73B
Shares Out	n/a
EPS (ttm)	2.63
PE Ratio	20.95
Forward PE	18.40
Dividend	1.29 (0.28%)
Ex-Dividend Date	Mar 28, 2025

Volume	1,246,214
Average Volume	1,053,924
Open	470.65
Previous Close	468.06
Day's Range	449.05 - 478.43
52-Week Range	379.70 - 1,032.20
Beta	0.24
RSI	61.95
Earnings Date	Aug 6, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QIU

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK